Screener
Protagonist Therapeutics PTGX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
FAQ
- What is Protagonist Therapeutics's total equity?
- Protagonist Therapeutics (PTGX) reported total equity of $841.54M in Q2 2026.
- How has Protagonist Therapeutics's total equity changed year-over-year?
- Protagonist Therapeutics's total equity increased by 26.0% year-over-year, from $668.02M to $841.54M.
- What is the long-term trend for Protagonist Therapeutics's total equity?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's total equity has grown at a 17.1% compound annual growth rate (CAGR), from $279.61M to $614.71M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Protagonist Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude